Leadership

Management Team

David Hallal, Chief Executive Officer

David Hallal is Chief Executive Officer of Alexion. Prior to becoming CEO, Mr. Hallal was Chief Operating Officer, leading strategic enterprise-wide initiatives that focused on diverse aspects of Alexion’s operations. He also has served on all key management decision-making committees, and in September 2014 was elected to the Company’s Board of Directors. Previously, Mr. Hallal was Alexion’s first Chief Commercial Officer.

Mr. Hallal joined Alexion in 2006 to launch the company’s commercial operations. He played a principal role in leading many of the company’s major growth initiatives and led the highly successful introductions of Soliris® (eculizumab) for both PNH and aHUS, while also building Alexion’s 50-country operating platform. In addition to his leadership of all commercial operations globally, Mr. Hallal has been responsible for country operations in each of Alexion’s affiliates in Europe/Middle East/Africa (EMEA), Japan, Australasia, and Latin America.

Mr. Hallal has more than 25 years of experience in the biopharmaceutical industry. Before joining Alexion, he held commercial leadership positions at OSI Eyetech, Biogen Idec and Amgen where he was involved in multiple blockbuster product launches in the areas of hematology, oncology, nephrology and immunology. Mr. Hallal holds a BA from the University of New Hampshire.

Vikas Sinha is Executive Vice President, Chief Financial Officer of Alexion, with responsibility for global financial management, corporate & strategic development, treasury, internal audit, investor relations, information technology, engineering, and real estate & security activities. Mr. Sinha has built these functions since 2005, when Alexion was based only in the US and had no approved product for sale.

Today, he leads global teams working in more than 20 countries to support the launches of Soliris in PNH and aHUS while building out Alexion’s global capabilities to support additional indications for Soliris and the launch of new transformative therapeutic candidates resulting from both internal development and strategic acquisitions.

Prior to joining Alexion, Mr. Sinha spent 11 years with Bayer AG in the US, Japan, Germany and Canada, rising to the position of Vice President and CFO of the Bayer Pharmaceutical organization in Japan and later, the US. Prior to Bayer, Mr. Sinha also held several positions of increasing responsibility with ANZ Bank and Citibank in South Asia.

Mr. Sinha holds a master's degree in business administration from the Asian Institute of Management. He is also a qualified Chartered Accountant from the Institute of Chartered Accountants of India and a Certified Public Accountant in the US.

Martin Mackay, Ph.D., Executive Vice President, Global Head of Research & Development

Martin Mackay, Ph.D. is Executive Vice President, Global Head of Research & Development of Alexion. In his role, Dr. Mackay is focused on significantly expanding Alexion’s global research and development organization, with a goal of accelerating the simultaneous development of multiple life-transforming drug candidates in debilitating and life-threatening ultra-rare disorders across a range of therapeutic areas. Dr. Mackay has more than 30 years of experience in drug discovery and development on a global scale.

Prior to joining Alexion, Dr. Mackay served as President, Research and Development at AstraZeneca, where he led all R&D functions worldwide, including discovery research, clinical development, regulatory affairs and key related R&D functions. He also held positions of increasing responsibility at Pfizer, rising to the position of President, Head of Pfizer Pharmatherapeutics, R&D, where he oversaw all aspects of small molecule discovery and development across multiple therapeutic areas. Earlier in his career, Dr. Mackay worked in the CIBA organization (now Novartis) and held positions within academia.

Dr. Mackay earned a Microbiology First Class Honors Degree from Heriot-Watt University, Scotland, and a Ph.D. in Molecular Genetics from the University of Edinburgh, Scotland.

Clare Carmichael is Executive Vice President, Chief Human Resources Officer of Alexion. She is responsible for Human Resources on a global basis, with the goal of continuing to build a cohesive organization with integrated, high performance teams.

Ms. Carmichael brings 30 years of HR experience with global pharmaceutical and biotech organizations to the organization. Prior to joining Alexion, she was SVP, Global Human Resources at Watson Pharmaceuticals, where she established and executed a strategy to successfully transition the workforce from a siloed U.S.-centric operation to a globally-focused matrix organization. Clare also held several HR positions at Schering-Plough, including Vice President of Global Human Resources at the Schering-Plough Research Institute, where she was selected for the global HR lead role for R&D to help drive cultural change in the organization. While at Schering-Plough, she also spearheaded integration activities when the company acquired Organon Biosciences. Clare also worked as the Vice President of HR at Eyetech Pharmaceuticals, leading the human resources function in the company from its post-IPO phase into the commercial phases of development and in Human Resources at Pharmacia Corporation.

Ms. Carmichael received a bachelor’s degree from Rider University and completed the University of Michigan Human Resources Executive Program.

Saqib Islam is Executive Vice President, Chief Strategy and Portfolio Officer of Alexion. His role at the company is to execute Alexion’s corporate growth strategies and contribute to its assessment and management of global operations.

Prior to joining Alexion, Mr. Islam worked for 18 years in international business management with a focus on business development, strategic decision-making and planning, and capital markets. He has an extensive background in the healthcare banking sector, having held positions of increasing responsibility in the investment banking divisions of Merrill Lynch, Morgan Stanley, and most recently, Credit Suisse Securities. Earlier in his career, Mr. Islam provided strategic analysis and advice to client firms across diverse industry segments for The Boston Consulting Group.

Mr. Islam received a bachelor’s degree from McGill University and a J.D. from Columbia Law School.

John Moriarty, J.D., Executive Vice President, General Counsel

John Moriarty is Executive Vice President, General Counsel of Alexion. In his role, he is responsible for overseeing all global legal matters as well as the Global Government Affairs and Corporate Communications teams. Since joining Alexion in 2012, his focus has been on developing these functions to support an increasing number of initiatives on behalf of patients in a growing number of countries.

Prior to joining Alexion, Mr. Moriarty was General Counsel and Chief Legal Officer at Elan Corporation plc, and served as a member of Elan’s Executive Management team. In his time at Elan, he was also Senior Vice President of Law, Litigation and Commercial Operations. Prior to that, Mr. Moriarty held several legal leadership positions at Amgen focused on litigation, and led the Amgen legal teams for the company’s commercial oncology, nephrology and hematology businesses. He has also worked as an attorney in the healthcare practice of a national law firm’s Washington, DC and New York offices and was a healthcare fraud prosecutor in the US Attorney’s Office and the Virginia Attorney General’s Office.

Mr. Moriarty holds a J.D. from the University of Georgia School of Law and a B.A. from the University of Virginia.

Julie O’Neill, Executive Vice President, Global Operations

Julie O’Neill is Executive Vice President, Global Operations of Alexion. Based out of our Alexion Pharma International Trading facility in Dublin, Ireland, Ms. O’Neill is responsible for global manufacturing operations, as well as Alexion’s complete supply chain and quality operations.

Ms. O’Neill brings considerable leadership experience to Alexion in global pharmaceutical operations. Before joining Alexion, she was Vice President of Operations and General Manager for Ireland at Gilead Sciences. While there, she established the company’s Irish subsidiary and plant operations and managed ongoing business expansion and operations, including supply chain manufacturing, packaging, quality control and assurance, and distribution.

Prior to these roles, Ms. O’Neill held leadership positions in operations, manufacturing and quality functions at Burnil Pharmacies and Helsinn Birex Pharmaceuticals. Presently, she serves as the Chairperson for the National Standards Authority of Ireland and is a member of the Governing Body of University College Cork.

Ms. O’Neill has a Bachelor’s of Science in Pharmacy from University of Dublin, Trinity College, and an MBA from University College Dublin – Smurfit School of Business.

Edward Miller is Senior Vice President, Global Chief Compliance Officer of Alexion. In his role, he leads all compliance functions globally for Alexion. Upon joining the company in 2014, Mr. Miller continued to build upon Alexion’s strong compliance program established over the past several years and reinforce the company’s commitment to ethical business practices.

Prior to joining Alexion, Mr. Miller served for 14 years at Boehringer Ingelheim, holding numerous compliance and legal leadership positions, including Vice President, Associate General Counsel, Global Litigation & Government Investigations; Vice President/Acting Global Compliance Officer; Vice President, Chief Compliance Officer and Head of Litigation; and Chief Compliance Officer, Head of Litigation. During his tenure there, he served as Boehringer’s first U.S. Chief Compliance Officer and also helped build a best-in-class global compliance function while assigned to Boehringer’s worldwide headquarters in Germany. Previously, Mr. Miller was a Senior Trial Attorney at the U.S. Department of Justice in Washington, D.C.

He obtained his undergraduate degree from Princeton University and law degree from Rutgers University School of Law.

Dominique Monnet, Senior Vice President, Chief Marketing Officer

Dominique Monnet is Senior Vice President, Chief Marketing Officer of Alexion and is responsible for the commercial operations of the Company in the United States and Latin America. Mr. Monnet also leads Alexion’s Global Franchises in PNH, aHUS, and metabolic disorders, and oversees the Company’s New Products and Business Operations functions.

Mr. Monnet has more than 25 years of biopharmaceutical experience. Prior to joining Alexion, he served as Vice President and General Manager for the Inflammation Business Unit at Amgen, where he was responsible for growing the Enbrel® franchise in a highly competitive market. Before that, he served as VP and Head of Amgen’s Global Marketing and Commercial Development, leading the company’s marketing strategy and new product launches in oncology, bone health, nephrology, cardiology, neuroscience and inflammation therapeutic areas. From 2002 to 2006, Mr. Monnet was based in Zug, Switzerland, where he served as VP, International Marketing and Business Operations. Prior to Amgen, Mr. Monnet held positions of increasing responsibility at Schering-Plough, including General Manager for the company’s UK and Ireland entity.

Mr. Monnet earned his undergraduate business degree from EDHEC Business School in Lille, France, and his MBA from INSEAD in Fontainebleau, France.

Carsten Thiel, Ph.D., Senior Vice President, EMEA & Asia Pacific

Carsten Thiel is Senior Vice President, Europe/Middle East/Africa & Asia Pacific of Alexion and is responsible for driving the Company’s global commercial operations in these regions, including maximizing the current portfolio as well as guiding the launch of anticipated new products and indications. Mr. Thiel also manages the regional and global functions located at the European headquarters in Switzerland.

Prior to joining Alexion, Mr. Thiel served as Vice President, Head of Europe at Amgen from 2011 to 2014. In this role, he led regional operations and was responsible for 10 products in hematology/oncology, nephrology, and bone disorders, and prepared for new product launches in inflammation and cardiology. Mr. Thiel also held various other senior leadership positions at Amgen, including General Manager, Germany, and General Manager, CEE, where he led all markets in Eastern Europe and established the company’s operations in Russia. He also served as Head of the Oncology Franchise in Europe during the time of several blockbuster product launches. Prior to Amgen, Mr. Thiel held several sales and marketing leadership roles across Europe at Roche.

Mr. Thiel has a Ph.D. in Molecular Biology and Biochemistry from the Max Planck Institute, Germany, and a Master’s Degree in Biochemistry from the University of Marburg, Germany.

Board of Directors

Leonard Bell, M.D., Chairman

Leonard Bell, M.D., is Chairman of Alexion’s Board of Directors. He was a principal founder of Alexion in 1992 and served as the Chief Executive Officer from the Company’s inception until April 2015. Under his leadership Alexion grew to become a global biopharmaceutical company with employees serving patients with severe and life-threatening disorders in 50 countries through fully integrated research, discovery, development, manufacturing and commercial capabilities.

Prior to founding Alexion, Dr. Bell was an attending physician at Yale-New Haven Hospital and Assistant Professor of Medicine and Pathology at the Yale University School of Medicine, where he also received his M.D. degree. He remains on the faculty of the Yale University School of Medicine as an Adjunct Assistant Professor of Medicine and Pathology. Dr. Bell received his A.B. degree in Philosophy from Brown University.

Felix J. Baker, Ph.D., Director

Felix J. Baker, Ph.D. has been a director of Alexion since June 2015. Dr. Baker is a Managing Partner of Baker Brothers Investments which he and his brother, Julian Baker, founded in 2000. Dr. Baker’s career as a fund-manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family.

Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school.

David R. Brennan, Director

David R. Brennan has been a director of Alexion since July 2014. He most recently served as Chief Executive Officer and Executive Director of AstraZeneca PLC, one of the world’s largest pharmaceutical companies, from 2006 to 2012. Mr. Brennan worked for AstraZeneca in increasing roles of responsibility from 1992 through 2012, including as Executive Vice President of North America from 2001 to 2006, and as Senior Vice President of Commercialization and Portfolio Management from 1999 to 2001. Prior to the merger of Astra AB and Zeneca Plc, he served as Senior Vice President of Business Planning and Development of Astra Pharmaceuticals LP, the American subsidiary of Astra AB. Mr. Brennan began his career in 1975 at Merck and Co. Inc., where he rose from Sales Representative in the U.S. Division to General Manager of Chibret International, a French subsidiary of Merck. Mr. Brennan currently serves on the Board of Directors of Innocoll, Inc. and Insmed Incorporated, and previously served on the Board of Directors of AstraZeneca PLC, Reed Elsevier PLC, and the Pharmaceutical Research & Manufacturers of America (PhRMA).

He received a BA in business administration from Gettysburg College, where he is a member of the Board of Trustees.

Mr. Brennan is a member of the Pharmaceutical Compliance & Quality Committee and the Strategy and Risk Committee.

M. Michele Burns, Director

M. Michele Burns has been a director of Alexion since July 2014. She currently serves as Center Fellow and Strategic Advisor, Stanford University Center on Longevity. She served in senior executive roles with Marsh & McLennan Companies, Inc. ("MMC"), including as Chief Executive Officer, Retirement Policy Center sponsored by MMC from 2011 to 2014, Chairwoman and Chief Executive Officer of Mercer LLC, a subsidiary of MMC, from 2006 to 2011, and Executive Vice President and Chief Financial Officer of MMC in 2006. From 2004 to 2006, Ms. Burns served as Executive Vice President, Chief Financial and Chief Restructuring Officer for Mirant Corporation. From 1999 to 2004 she worked in increasing roles of responsibility at Delta Air Lines, serving as Executive Vice President and Chief Financial Officer of Delta from 2000 to 2004. Ms. Burns began her career with Arthur Andersen, and over an 18-year tenure rose to Senior Partner, leading Andersen's Southern Region Federal Tax Practice, heading its U.S. Healthcare Tax Practice and its Southeastern Region Financial Services Tax Practice, and serving on its Global Advisory Council. Ms. Burns currently serves on the Board of Directors of The Goldman Sachs Group, Inc., Cisco Systems, Inc., and Circle Internet Financial, Ltd. She also serves on the Executive Board and as Treasurer of the Elton John Aids Foundation. She previously served on the Board of Directors of Wal-Mart Stores, Inc., Ivan Allen Company, and Orbitz, LLC.

Ms. Burns received a BA in business administration and a Master of Accountancy from the University of Georgia.

Ms. Burns is Chair of the Strategy and Risk Committee and a member of the Compensation Committee and the Nominating & Corporate Governance Committee.

Christopher J. Coughlin, Director

Christopher J. Coughlin has been a director of Alexion since July 2014. He is currently a Senior Advisor, McKinsey & Co., where he has served since 2012. He served as Advisor to the Chairman and CEO of Tyco International Ltd., a global provider of diversified products, services and industries, from 2010 to 2012, and as Executive Vice President and Chief Financial Officer of Tyco from 2005 to 2010 and during a period of significant international growth and restructuring. Mr. Coughlin previously served at the Interpublic Group of Companies, Inc. as Executive Vice President, Chief Operating Officer from 2003 to 2004. From 1998 to 2003, he served as Executive Vice President and Chief Financial Officer of Pharmacia Corporation. From 1997 to1998 he was President, International at Nabisco Group Holdings and from 1996 to 1997 was Executive Vice President and Chief Financial Officer of Nabisco. From 1981 to 1996, Mr. Coughlin held various positions with Sterling Winthrop Incorporated, including Chief Financial Officer. Mr. Coughlin currently serves on the Board of Directors of Allergan plc and Dun & Bradstreet. He previously served on the Board of Directors of Covidien (acquired by Medtronic), Actavis (which acquired Allergan), Forest Laboratories (acquired by Actavis plc), Dipexium Pharmaceuticals, Inc., The Interpublic Group of Companies, Monsanto Company, and Perrigo Company.

Mr. Coughlin received a BS in accounting from Boston College.

Mr. Coughlin is Chair of the Audit & Finance Committee and a member of the Pharmaceutical Compliance & Quality Committee.

David Hallal, Chief Executive Officer

David Hallal is Chief Executive Officer of Alexion. Prior to becoming CEO, Mr. Hallal was Chief Operating Officer, leading strategic enterprise-wide initiatives that focused on diverse aspects of Alexion’s operations. He also has served on all key management decision-making committees, and in September 2014 was elected to the Company’s Board of Directors. Previously, Mr. Hallal was Alexion’s first Chief Commercial Officer.

Mr. Hallal joined Alexion in 2006 to launch the company’s commercial operations. He played a principal role in leading many of the company’s major growth initiatives and led the highly successful introductions of Soliris® (eculizumab) for both PNH and aHUS, while also building Alexion’s 50-country operating platform. In addition to his leadership of all commercial operations globally, Mr. Hallal has been responsible for country operations in each of Alexion’s affiliates in Europe/Middle East/Africa (EMEA), Japan, Australasia, and Latin America.

Mr. Hallal has more than 25 years of experience in the biopharmaceutical industry. Before joining Alexon, he held commercial leadership positions at OSI Eyetech, Biogen Idec and Amgen where he was involved in multiple blockbuster product launches in the areas of hematology, oncology, nephrology and immunology. Mr. Hallal holds a BA from the University of New Hampshire.

John T. Mollen, Director

Jack Mollen has been a director of Alexion since April 2014. He was most recently special advisor to the Chairman of EMC Corporation and previously served as EMC's Executive Vice President, Human Resources (HR) for 14 years. While at EMC, Mr. Mollen led the global human resources function to ensure the availability of world-class talent to drive business success and his responsibilities included executive, leadership, and employee development; compensation and benefits; staffing; and all of the people-related aspects of acquisition integration. Prior to joining EMC, Mr. Mollen was Vice President of Human Resources at Citigroup Inc. Mr. Mollen serves as a director for a number of not-for-profit and professional boards, including the New England Healthcare Institute, the HR Policy Association, Center on Executive Compensation, Worcester Polytechnic Institute Board of Trustees and Chairman of its Compensation Committee, and as an advisory board member for Working Mother magazine.

Mr. Mollen received a bachelor's degree in economics from St. John Fisher College in Rochester, N.Y., and a master's degree in labor relations from St. Francis University in Loretto, Pa.

Mr. Mollen is Chair of the Compensation Committee and a member of the Audit & Finance Committee and the Nominating & Corporate Governance Committee.

R. Douglas Norby, Lead Independent Director

R. Douglas Norby has been a director of Alexion since September 1999 and was appointed lead independent director in October 2014. In addition to serving on Alexion’s Board, he has held positions of increasing responsibility at many companies, including serving as Senior Vice President and Chief Financial Officer of Tessera, Inc., a provider of intellectual property for advanced semiconductor packaging, and as Senior Vice President and Chief Financial Officer of Zambeel, Inc., a data storage systems company. Mr. Norby has also served as Senior Vice President and Chief Financial Officer of Novalux, Inc., a manufacturer of lasers for optical networks, as Executive Vice President and Chief Financial Officer of LSI Logic Corporation, a semiconductor company, as Senior Vice President and Chief Financial Officer of Mentor Graphics Corporation, a software company, and as President and Chief Operating Officer at Lucasfilm, Ltd., an entertainment company. His pharmaceutical experience includes serving as President of Pharmetrix Corporation, a drug delivery company, and as Senior Vice President and Chief Financial Officer of Syntex Corporation, a pharmaceutical company. He currently serves on the Board of Directors for several other companies, including STATS Chip PAC, Ltd, Singulex, Inc. and MagnaChip Semiconductor.

Mr. Norby received a B.A. in Economics from Harvard University and an M.B.A. from Harvard Business School.

Mr. Norby is a member of the Audit & Finance Committee, the Compensation Committee and the Nominating & Corporate Governance Committee.

Alvin S. Parven, Director

Alvin S. Parven has been a director of Alexion since May 1999. He has been President of ASP Associates, a management and strategic consulting firm, since 1997. Prior to that, Mr. Parven held positions of increasing responsibility within the Aetna family of companies, serving as Vice President at Aetna Business Consulting, Vice President, Operations at Aetna Health Plans and Vice President, Pension Services.

Mr. Parven received his B.A. from Northeastern University.

Mr. Parven is a member of the Audit & Finance Committee, the Compensation Committee and the Nominating & Corporate Governance Committee.

Andreas Rummelt, Ph.D., Director

Dr. Andreas Rummelt has been a director of Alexion since February 2010. He has held executive management positions internationally for more than 20 years in the pharmaceutical industry, focused in the areas of manufacturing, quality and technical matters. He is currently the CEO and Partner of InterPharmaLink AG, a management consulting firm focused on advising companies in the healthcare industry. Dr. Rummelt was Group Head of Quality Assurance and Technical Operations at Novartis, and served as a member of the Executive Committee there. He also held various positions of increasing responsibility in development for Sandoz Pharma Ltd including CEO, Head of Worldwide Technical Research and Development, Head of Technical Operations of the Novartis Pharmaceuticals Division. He currently serves on the Board of Directors at Acino, Xellia Pharmaceuticals and Selcia, Ltd.

Dr. Rummelt earned his Ph.D. in Pharmaceutical Sciences from the University of Erlangen-Nuremberg, Germany. He received executive training in general management and leadership from IMD in Lausanne (Switzerland), INSEAD in Fontainebleau (France), and Harvard Business School in Cambridge (USA).

Dr. Rummelt is Chair of the Pharmaceutical Compliance & Quality Committee and a member of the Strategy and Risk Committee.

Ann Veneman, J.D., Director

Ann M. Veneman has been a director of Alexion since May 2010. Prior to this, she has served as Executive Director of the United Nations Children's Fund (UNICEF), leading a global organization which supports multiple aspects of child health, nutrition, safety and education in over 150 countries and territories. Before joining UNICEF, Ms. Veneman was the first woman to serve as Secretary of the U.S. Department of Agriculture (USDA), leading an organization of 110,000 employees with an annual budget of $113 billion. She has also worked as California’s Secretary of Food and Agriculture. Ms. Veneman is a co-leader of the Nutrition and Physical Activity Initiative at the Bipartisan Policy Center and is a member of the Council on Foreign Relations. An attorney by training, she has practiced law in Washington, D.C. and California.

Ms. Veneman earned her Bachelor's degree in political science from the University of California, Davis; a Master's degree in public policy from the University of California, Berkeley; and a Juris Doctorate from the University of California, Hastings College of Law.

Ms. Veneman is Chair of the Nominating & Corporate Governance Committee and a member of the Pharmaceutical Compliance & Quality Committee and the Strategy and Risk Committee.